Proposed acquisition supports the Novartis oncology strategy in hormone receptor positive, human epidermal growth factor receptor two-negative (HR+/HER2-) breast cancer The lead asset, SNV4818, currently in a Phase 1/2 clinical study, is designed to selectively target PI3Kα mutations in breast cancer while sparing wild-type PI3Kα, thus reducing unwanted side effects and improving tolerabilityAddresses a well‑defined patient population with significant unmet need -- approximately 40% of HR+/HER2- breast canc ...

Group 1 - AbbVie Inc. is recognized as one of the 15 Dividend Stocks to Buy for Steady Income, indicating its strong position in the market for consistent returns [1] - AbbVie has entered into a multi-year agreement with Alloy Therapeutics to develop a new antibody platform aimed at discovering potent and specific antibodies for challenging targets [2][3] - The collaboration allows AbbVie to enhance its research capabilities and expand its pipeline with targeted therapies, leveraging Alloy's widely adopted ATX-Gx platform used by over 200 partners [3][4] Group 2 - AbbVie continues to reinvest its revenue into research and development, adapting its platform to meet the evolving demands in antibody discovery [4] - The company focuses on various therapeutic areas, including immunology, oncology, aesthetics, neuroscience, and eye care, showcasing its diverse portfolio [4]

Core Insights - RBC Capital views Eli Lilly's retatrutide as a significant growth driver despite mixed trial results, particularly in terms of tolerability and A1C reductions compared to Mounjaro for type 2 diabetes patients [1][2] - The drug is considered a viable option for patients prioritizing weight loss, which is a critical factor for a specific patient demographic [2] - RBC expects retatrutide to be a key component in Eli Lilly's growth strategy, projecting a launch in 2027 and estimating 2030 sales at $4.9 billion, below the consensus estimate of $5.4 billion [2] Company Overview - Eli Lilly and Company develops, manufactures, discovers, and sells pharmaceutical products across various therapeutic areas, including oncology, diabetes, immunology, and neuroscience [3]

Core Viewpoint - The article discusses the challenges in finding equity income, highlighting low dividend yields in both the US and global markets, and emphasizes the importance of companies with strong dividend histories and wide economic moats for steady income generation [1][2][4]. Dividend Yield Trends - The Morningstar US Market Index had a dividend yield of under 1.2% in Q1 2026, which is historically low, while the Morningstar Global Markets ex-US Index offered a yield of 2.6% [1]. - Stock prices have increased significantly, but dividend payments have not kept pace, with a notable shift towards share buybacks and investments in artificial intelligence [2]. Sector Performance - There has been a rebound in sectors such as industrials, energy, and consumer defensives, which has supported total returns but kept yields lower [3]. - Dividend-paying stocks outside the U.S. have outperformed the broader market for some time, with around 1,500 companies globally under analyst coverage and assigned moat ratings [3]. Moat Analysis - Companies with wide moats tend to sustain profitability more consistently and have historically cut dividends less often compared to those with narrow or no moats [4]. Methodology for Stock Selection - The selection criteria for the list of dividend stocks included companies that have raised dividends for at least 10 consecutive years and have yields above 0.5% as of March 19 [6]. Company Highlights - **Eli Lilly and Company (NYSE: LLY)**: - Dividend yield as of March 19 is 0.75%. Recent study results for retatrutide indicate it may be a viable option for patients prioritizing weight loss, with projected 2030 sales at $4.9 billion [9][10][11]. - **S&P Global Inc. (NYSE: SPGI)**: - Dividend yield as of March 19 is 0.91%. The price recommendation was raised to $495, citing stronger issuance trends, with February billed issuance rising 22% year-over-year [12][13]. - The acquisition of Enertel AI Corporation enhances S&P Global's capabilities in AI-driven power price forecasting, providing a more comprehensive view of the power market [14][15].

Core Viewpoint - A class action lawsuit has been filed against Soleno Therapeutics, Inc. regarding allegations of securities fraud and unlawful business practices related to its product, DCCR [2][3]. Group 1: Class Action Details - Investors who suffered losses from their investment in Soleno are encouraged to contact Pomerantz LLP to join the class action lawsuit [1]. - The deadline to request appointment as Lead Plaintiff is May 5, 2026, for those who purchased Soleno securities during the Class Period [2]. Group 2: Product and Market Impact - Scorpion Capital published a report on August 15, 2025, labeling DCCR as overpriced and potentially unsafe for children, leading to a stock price drop of $5.73 per share, or 7.41%, closing at $71.63 [2][3]. - Following the disclosure of a patient death related to DCCR on September 10, 2025, Soleno's stock fell by $13.49 per share, or 19.21%, to close at $56.72 [3]. - On November 4, 2025, Soleno reported an 8% discontinuation rate of DCCR due to adverse effects, which the CEO attributed to the negative impact of the Scorpion report on the product's launch trajectory [4]. - The stock price further declined by $16.98 per share, or 26.59%, closing at $46.87 on November 5, 2025 [5].

England’s drug price regulator will have to reconsider its decision to rule out using Eli Lilly’s Alzheimer’s drug in the state-run National Health Service, following a successful appeal by the US drugmaker https://t.co/fWXon8Qsap ...

Core Insights - The company is focusing on the 'Eton Cares' patient support program to eliminate financial barriers and enhance physician prescribing confidence [1] - Galzin's performance surpassed expectations, achieving 300 active patients within one year by converting users from non-FDA-approved over-the-counter zinc supplements [1] - The acquisition of Hemangiol aligns with a strategy to acquire under-optimized assets and leverage Eton's specialized infrastructure in rare diseases [1] Financial Performance - The adjusted EBITDA margin increased to 29% from 18%, attributed to disciplined cost management and a shift towards higher-margin rare disease assets [2] - Q4 revenue grew by 83% year-over-year, driven by increased sales of Alkindi Sprinkle and contributions from Incralex, Galzan, and Candivy [2] - Revenue is projected to more than double in 2025 following the successful launch of three cornerstone products: Incrolix, Galzyn, and Kinduvi [2] Future Guidance - The company projects revenue exceeding $110 million in 2026 with adjusted EBITDA margins of at least 30% as the portfolio scales [2] - A new goal, '200 by 27,' aims for a $200 million revenue run rate by the end of 2027 through organic growth and at least one additional acquisition [2] - The launch strategy for Desmota includes a 90-day pilot targeting adult endocrinologists, addressing a market three times larger than the pediatric population [2] Long-term Targets - Long-term financial targets include achieving a 50% adjusted EBITDA margin by 2028 and reaching $500 million in annual revenue by 2030 [2] - The R&D pipeline is expected to be highly active in 2026, with five clinical studies planned to support label expansions and new NDAs [2]

Core Viewpoint - The law firm Kirby McInerney LLP is reminding investors of Corcept Therapeutics Incorporated about the upcoming lead plaintiff deadline for a class action lawsuit related to the company's securities during a specified class period [1]. Summary by Sections Lawsuit Details - The lawsuit alleges that Corcept misrepresented the strength of clinical trials supporting the New Drug Application (NDA) for relacorilant, claiming it was "powerful support" for FDA approval, while the FDA had raised concerns about the adequacy of clinical evidence [3]. - Corcept communicated confidence in the NDA submission, stating there were no anticipated impediments to approval, despite known risks regarding the NDA's approval status [3]. Impact of FDA Communication - On December 31, 2025, Corcept disclosed that the FDA issued a Complete Response Letter (CRL) indicating it could not assess a favorable benefit-risk profile for relacorilant without additional evidence, leading to a significant drop in share price by $35.40, or approximately 50.4%, from $70.20 to $34.80 [4]. - Following the end of the class period, the FDA released a redacted CRL detailing concerns about the clinical studies' sufficiency, resulting in a further decline in share price by $4.74, or approximately 10.6%, from $44.61 to $39.87 [5].

Core Insights - The article summarizes the successful experiences of multinational corporations (MNCs) from the US, Europe, and Japan, providing insights for Chinese companies in their globalization efforts. It highlights the common motivations for going global, such as overcoming growth ceilings, avoiding trade barriers, and optimizing cost structures, while also noting the distinct paths taken by different economies based on their unique resources and institutional frameworks [3]. Group 1: United States - US companies focus on high value-added sectors and technological leadership, driven by the need to counter domestic antitrust regulations and optimize production factors. The emphasis on supply chain security has become increasingly important in overseas investment decisions [3][4]. - The US has established a strong technological moat in high value-added fields, particularly in the tech industry, characterized by leading advantages, global tech discourse control, and a shift towards digital economy-driven globalization [3][4][18]. - As of 2022, US MNCs had nearly 40,000 foreign affiliates, generating over $27 trillion in revenue and $3 trillion in net profit, with significant contributions from Europe and the Asia-Pacific region [10][12]. Group 2: Europe - European companies expand overseas primarily due to limited domestic resources and high production costs, necessitating global resource integration to maintain competitiveness [4][42]. - The technological foundation of European firms is characterized by comprehensive capabilities that span from basic research to industrial application, creating significant barriers across the value chain [4][44]. - As of 2023, EU MNCs had over 200,000 foreign affiliates, generating nearly €20 trillion in revenue, with a significant portion coming from intra-European markets [45][49]. Group 3: Japan - Japanese companies transitioned from a "trade nation" to an "investment nation," driven by internal market saturation and external pressures such as trade friction and currency appreciation, prompting a shift towards overseas production [5][65]. - The localization of production has been crucial for Japanese firms, particularly in the automotive sector, achieving an 80% localization rate in overseas production [5][66]. - Japan's unique globalization path emphasizes capital and knowledge-intensive industries, with a focus on lean manufacturing and integrated support from trading companies [5][66].

Core Viewpoint - Collegium Pharmaceutical is expanding its position in the ADHD market through the acquisition of AZSTARYS and related subsidiaries from Corium Therapeutics [2] Group 1: Acquisition Details - The acquisition of AZSTARYS significantly enhances Collegium's portfolio in the ADHD sector [2] - The call includes participation from key executives, including the President and CEO, Chief Commercial Officer, and Chief Financial Officer, indicating a strong leadership presence for the discussion [2] Group 2: Investor Communication - The company emphasizes that the information presented is not promotional and includes forward-looking statements under the safe harbor provision of the Private Securities Litigation Reform Act of 1995 [3] - There is a caution regarding the potential differences between future results and current expectations, highlighting the inherent risks and uncertainties [4]